Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Keratosis, Actinic
Conditions
Keratosis, Actinic
Trial Timeline
Oct 24, 2022 → Jul 1, 2027
NCT ID
NCT05387525About Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel is a approved stage product being developed by Almirall for Keratosis, Actinic. The current trial status is active. This product is registered under clinical trial identifier NCT05387525. Target conditions include Keratosis, Actinic.
What happened to similar drugs?
4 of 20 similar drugs in Keratosis, Actinic were approved
Approved (4) Terminated (0) Active (16)
🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05387525 | Approved | Active |
Competing Products
20 competing products in Keratosis, Actinic